Suppression of EBNA1 expression inhibits growth of EBV-positive NK/T cell lymphoma cells

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1602-1606

  Ian, Mo X ^a,b   Lan, Su Z ^a,c   Cheng, Zhang F ^a   Dan, He ^a   Qiong, Lu H ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b People's Hospital of Guangxi Province   (China)

^c NONE   (China)

Author keywords

EBNA1; HANK1 cell line; Lymphoma; NK cell type; p27; RNAi

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; PROTEIN P27; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; DRUG INHIBITION; DRUG TARGETING; EPSTEIN BARR VIRUS; GENE SILENCING; GROWTH INHIBITION; LATENT VIRUS INFECTION; NATURAL KILLER T CELL; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS CARCINOGENESIS; WESTERN BLOTTING;

EID: 54349093290     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6564     Document Type: Article

References (31)

1. Chan JKC, Jaffe ES, Ralfkiaer ER. Extranodal NK/T cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France 2001; 204-7.
2. Chim CS, Ma SY, Au WY, Choy C, Lie AW, Liang A, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103:216-21.
3. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24:612-8.
4. Li YX, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24:181-9.
5. Isobe K, Uno T, Tamaru J, Kawakami H, Ueno N, Wakita H, et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106:609-15.
6. Kim GE, Cho JH, Yang WI, Chung EJ, Suh CO, Park KR, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18:54-63.
7. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99:1016-20.
8. Bang SM, Kim YK, Park YH, Sohn SK, Lee JJ, Cho EK, et al. High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leuk Lymphoma 2005; 46:1599-604.
9. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130:561-7.
10. Chiang AK, Tao Q, Srivastava G, Ho FC. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer 1996; 68:285-90.
11. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of ten years. Ann Oncol 2005; 16:206-14.
12. Knight JS, Sharma N, Robertson ES. SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 2005; 25:1749-63.
13. Uner AH, Saglam A, Han U, Hayran M, Sungur A, Ruacan S. PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leuk lymphoma 2005; 46:1463-70.
14. Kip1 levels during tumor development. Cancer cell 2006; 9:75-6.
15. Altmann M, Pich D, Ruiss R, Wang J, Sugden B, Hammerschmidt W. Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes. Proc Natl Acad Sci USA 2006; 103:14188-93.
16. Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 2006; 346:385-93.
17. Ohri SS, Vashishta A, Proctor M, Fusek M, Vetvicka V. Depletion of procathepsin D gene expression by RNA interference: A potential therapeutic target for breast cancer. Cancer Biol Ther 2007; 6:1081-7.
18. Zhang ZH, Chen Y, Zhao HJ, Xie CY, Ding J, Hou YT. Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo. Cancer Biol Ther 2007; 6:587-95.
19. + phenotype and associated with the Epstein-Barr virus. Br J Haematol 1998; 103:669-77.
20. Xiang-Lan M, Zu-Lan S, Dan H, Bi-Hong S, Ya-Qin P, Han-Liang L. Skp2/p27 expression profile is correlated with Epstein-Barr virus status in extranodal nasal-type natural killer cell lymphoma. Transl Res 2008; 151:303-8.
21. Grund EM, Muise-Helmericks RC. Cost efficient and effective gene transfer into the human natural killer cell line, NK92. J Immunol Methods 2005; 296:31-6.
22. Aarskog NK, Vedeler CA. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 2000; 107:494-8.
23. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14:1673-6.
24. Yong W, Zheng W, Zhang Y, Zhu J, Wei Y, Zhu D, Li J. L-sparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78:163-7.
25. Aviles A, Neri N, Fernandez R, Calva A, Huerta-Guzman J, Nambo MJ. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20:13-7.
26. Trejo-Avila L, Elizondo-González R, Trujillo-Murillo Kdel C, Zapata-Benavides P, Rodríguez-Padilla C, Rivas-Estilla AM. Antiviral therapy: inhibition of Hepatitis C Virus expression by RNA interference directed against the NS5B region of the viral genome. Ann Hepatol 2007; 6:174-80.
27. McSwiggen JA, Seth S. A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. Expert Opin Biol Ther 2008; 8:299-313.
28. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol Ther 2006; 14:883-92.
29. DeVincenzo J, Cehelsky JE, Alvarez R, Elbashir S, Harborth J, Toudjarska I, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77:225-31.
30. Hong M, Murai Y, Kutsuna T, Takahashi H, Nomoto K, Cheng CM, et al. Suppression of Epstein-Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells. J Cancer Res Clin Oncol 2006; 132:1-8.
31. Flavell JR, Baumforth KR, Wood VH, Davies GL, Wei W, Reynolds GM, et al. Downregulation of the TGFbeta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 2008; 111:292-301.